Comparator : placebo (unspecified)

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Diabetes Mellitus Type 2Type 2 Diabetes Mellitus

Phase 3

Sitagliptin Added-on to Insulin Study (0431-051)

CompletedNCT00395343

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2006-12-11End: 2008-10-13Updated: 2017-05-12

Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)

CompletedNCT00485758

Merck Sharp & Dohme LLCDiabetes Mellitus Type 2

Start: 2007-07-31End: 2008-08-31Updated: 2015-10-12

Related Papers

Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control

Vascular Health and Risk Management2015-02-019 citations

How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014

Figshare2014-01-01

Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.

2012-06-0114 citations

Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.

2012-03-0810 citations